Literature DB >> 31369724

The Impact of Substance Abuse on Heart Failure Hospitalizations.

Marin Nishimura1, Harpreet Bhatia1, Janet Ma1, Stephen D Dickson1, Laith Alshawabkeh1, Eric Adler1, Alan Maisel1, Michael H Criqui2, Barry Greenberg1, Isac C Thomas3.   

Abstract

BACKGROUND: The burden of substance abuse among patients with heart failure and its association with subsequent emergency department visits and hospital admissions are poorly characterized.
METHODS: We evaluated the medical records of patients with a diagnosis of heart failure treated at the University of California-San Diego from 2005 to 2016. We identified substance abuse via diagnosis codes or urine drug screens. We used Poisson regression to evaluate the incidence rate ratios (IRR) of substance abuse for emergency department visits or hospitalizations with a primary diagnosis of heart failure, adjusted for age, sex, race, medical insurance status, and medical diagnoses.
RESULTS: We identified 11,268 patients with heart failure and 15,909 hospital encounters for heart failure over 49,712 person-years of follow-up. Substance abuse was diagnosed in 15.2% of patients. Disorders such as methamphetamine abuse (prevalence 5.2%, IRR 1.96, 95% confidence interval [CI] 1.85-2.07), opioid use and abuse (8.2%, IRR 1.54, 95% CI 1.47-1.61), and alcohol abuse (4.5%, IRR 1.51, 95% CI 1.42-1.60) were associated with a greater number of hospital encounters for heart failure, with associations that were comparable to diagnoses such as atrial fibrillation (37%, IRR 1.78, 95% CI 1.73-1.84), ischemic heart disease (24%, IRR 1.67, 95% CI 1.62-1.73), and chronic kidney disease (26%, IRR 1.57, 95% CI 1.51-1.62).
CONCLUSIONS: Although less prevalent than common medical comorbidities in patients with heart failure, substance-abuse disorders are significant sources of morbidity that are independently associated with emergency department visits and hospitalizations for heart failure. Greater recognition and treatment of substance abuse may improve outcomes among patients with heart failure.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Heart failure; Readmission; Substance abuse

Mesh:

Substances:

Year:  2019        PMID: 31369724      PMCID: PMC6980459          DOI: 10.1016/j.amjmed.2019.07.017

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

Review 1.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

2.  Rehospitalizations among patients in the Medicare fee-for-service program.

Authors:  Stephen F Jencks; Mark V Williams; Eric A Coleman
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245

3.  The Impact of Opioid Risk Reduction Initiatives on High-Dose Opioid Prescribing for Patients on Chronic Opioid Therapy.

Authors:  Michael Von Korff; Sascha Dublin; Rod L Walker; Michael Parchman; Susan M Shortreed; Ryan N Hansen; Kathleen Saunders
Journal:  J Pain       Date:  2015-10-22       Impact factor: 5.820

4.  Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.

Authors:  Paul A Heidenreich; Nancy M Albert; Larry A Allen; David A Bluemke; Javed Butler; Gregg C Fonarow; John S Ikonomidis; Olga Khavjou; Marvin A Konstam; Thomas M Maddox; Graham Nichol; Michael Pham; Ileana L Piña; Justin G Trogdon
Journal:  Circ Heart Fail       Date:  2013-04-24       Impact factor: 8.790

5.  Timing and Causes of Readmission After Acute Heart Failure Hospitalization-Insights From the Heart Failure Network Trials.

Authors:  Justin M Vader; Shane J LaRue; Susanna R Stevens; Robert J Mentz; Adam D DeVore; Anuradha Lala; John D Groarke; Omar F AbouEzzeddine; Shannon M Dunlay; Justin L Grodin; Victor G Dávila-Román; Lisa de Las Fuentes
Journal:  J Card Fail       Date:  2016-04-28       Impact factor: 5.712

6.  Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction.

Authors:  Natalie A Bello; Brian Claggett; Akshay S Desai; John J V McMurray; Christopher B Granger; Salim Yusuf; Karl Swedberg; Marc A Pfeffer; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2014-05-29       Impact factor: 8.790

7.  Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project.

Authors:  Mark D Huffman; Jarett D Berry; Hongyan Ning; Alan R Dyer; Daniel B Garside; Xuan Cai; Martha L Daviglus; Donald M Lloyd-Jones
Journal:  J Am Coll Cardiol       Date:  2013-04-09       Impact factor: 24.094

Review 8.  The Cardiac Complications of Methamphetamines.

Authors:  Elizabeth D Paratz; Neil J Cunningham; Andrew I MacIsaac
Journal:  Heart Lung Circ       Date:  2015-11-28       Impact factor: 2.975

9.  Methamphetamine-Associated Congestive Heart Failure: Increasing Prevalence and Relationship of Clinical Outcomes to Continued Use or Abstinence.

Authors:  Sean Sliman; Jill Waalen; David Shaw
Journal:  Cardiovasc Toxicol       Date:  2016-10       Impact factor: 3.231

10.  Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy.

Authors:  Stephan Schürer; Karin Klingel; Marcus Sandri; Nicolas Majunke; Christian Besler; Reinhard Kandolf; Philipp Lurz; Michael Luck; Pia Hertel; Gerhard Schuler; Axel Linke; Norman Mangner
Journal:  JACC Heart Fail       Date:  2017-06       Impact factor: 12.035

View more
  6 in total

Review 1.  Stimulant Drugs of Abuse and Cardiac Arrhythmias.

Authors:  Paari Dominic; Javaria Ahmad; Hajra Awwab; Md Shenuarin Bhuiyan; Christopher G Kevil; Nicholas E Goeders; Kevin S Murnane; James C Patterson; Kristin E Sandau; Rakesh Gopinathannair; Brian Olshansky
Journal:  Circ Arrhythm Electrophysiol       Date:  2021-12-28

2.  National rates and trends of tobacco and substance use disorders among atrial fibrillation hospitalizations.

Authors:  Rajkumar Doshi; Mihir Dave; Monil Majmundar; Ashish Kumar; Devina Adalja; Mariam Shariff; Rupak Desai; Boback Ziaeian; Saraschandra Vallabhajosyula
Journal:  Heart Lung       Date:  2020-12-21       Impact factor: 2.210

3.  Trends of Substance Use among Individuals with Cardiovascular Disease in the United States, 2015-2019.

Authors:  Yeonwoo Kim; Sehun Oh; Paul J Fadel; Christopher P Salas-Wright; Michael G Vaughn
Journal:  Int J Environ Res Public Health       Date:  2022-01-05       Impact factor: 3.390

4.  Echocardiographic Parameters and Outcomes in Methamphetamine-Associated Heart Failure: A Propensity Score-Weighted Analysis.

Authors:  Jakrin Kewcharoen; Andrew K Chang; Purvi Parwani; Gary Fraser; Aditya Bharadwaj; Ahmed Seliem; Diane Tran; Liset Stoletniy; Antoine Sakr; Dmitry Abramov
Journal:  Cardiol Res       Date:  2022-04-05

5.  US life expectancy stalls due to cardiovascular disease, not drug deaths.

Authors:  Neil K Mehta; Leah R Abrams; Mikko Myrskylä
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-16       Impact factor: 11.205

6.  Benefits and Risks of Moderate Alcohol Consumption on Cardiovascular Disease: Current Findings and Controversies.

Authors:  Gemma Chiva-Blanch; Lina Badimon
Journal:  Nutrients       Date:  2019-12-30       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.